ECSP109883A - Combinaciones sinérgicas de antagonistas de vr-1 e inhibidores de cox-2 - Google Patents

Combinaciones sinérgicas de antagonistas de vr-1 e inhibidores de cox-2

Info

Publication number
ECSP109883A
ECSP109883A EC2010009883A ECSP109883A ECSP109883A EC SP109883 A ECSP109883 A EC SP109883A EC 2010009883 A EC2010009883 A EC 2010009883A EC SP109883 A ECSP109883 A EC SP109883A EC SP109883 A ECSP109883 A EC SP109883A
Authority
EC
Ecuador
Prior art keywords
cox
antagonists
inhibitors
synergic combinations
synergic
Prior art date
Application number
EC2010009883A
Other languages
English (en)
Inventor
Alyson Fox
Mark Nash
Bindi Sohal
Elliot Lilley
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38828679&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP109883(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP109883A publication Critical patent/ECSP109883A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G11—INFORMATION STORAGE
    • G11B—INFORMATION STORAGE BASED ON RELATIVE MOVEMENT BETWEEN RECORD CARRIER AND TRANSDUCER
    • G11B33/00—Constructional parts, details or accessories not provided for in the other groups of this subclass
    • G11B33/02—Cabinets; Cases; Stands; Disposition of apparatus therein or thereon
    • G11B33/04—Cabinets; Cases; Stands; Disposition of apparatus therein or thereon modified to store record carriers
    • G11B33/0405—Cabinets; Cases; Stands; Disposition of apparatus therein or thereon modified to store record carriers for storing discs
    • G11B33/0411—Single disc boxes
    • G11B33/0422—Single disc boxes for discs without cartridge
    • G11B33/0427—Single disc boxes for discs without cartridge comprising centre hole locking means

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una combinación sinérgica de un antagonista del receptor vanilloide VR-1 y un fármaco anti-inflamatorio no esteroideo, o una sal o solvato farmacéuticamente aceptable de cualquiera o ambos compuestos.
EC2010009883A 2007-07-18 2010-01-18 Combinaciones sinérgicas de antagonistas de vr-1 e inhibidores de cox-2 ECSP109883A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07112679 2007-07-18

Publications (1)

Publication Number Publication Date
ECSP109883A true ECSP109883A (es) 2010-02-26

Family

ID=38828679

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010009883A ECSP109883A (es) 2007-07-18 2010-01-18 Combinaciones sinérgicas de antagonistas de vr-1 e inhibidores de cox-2

Country Status (22)

Country Link
US (1) US8618120B2 (es)
EP (1) EP2178562B1 (es)
JP (1) JP5755879B2 (es)
KR (1) KR20100039410A (es)
CN (1) CN101754774B (es)
AR (1) AR067631A1 (es)
AU (1) AU2008277627B2 (es)
BR (1) BRPI0813825A2 (es)
CA (1) CA2692655A1 (es)
CL (1) CL2008002096A1 (es)
CO (1) CO6270239A2 (es)
EA (1) EA201000103A1 (es)
EC (1) ECSP109883A (es)
ES (1) ES2648225T3 (es)
GT (1) GT201000012A (es)
MA (1) MA31563B1 (es)
MY (1) MY147952A (es)
NZ (1) NZ582496A (es)
TN (1) TN2010000004A1 (es)
TW (1) TW200914022A (es)
WO (1) WO2009010529A1 (es)
ZA (1) ZA201000076B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0412769D0 (en) 2004-06-08 2004-07-07 Novartis Ag Organic compounds
US9290489B2 (en) 2012-07-06 2016-03-22 Duke University Activation of TRPV4 ion channel by physical stimuli and critical role for TRPV4 in organ-specific inflammation and itch
US9873669B2 (en) 2014-01-09 2018-01-23 Eisai R&D Management Co., Ltd. Cationic lipid
WO2016028325A1 (en) 2014-08-22 2016-02-25 Duke University Trpa1 and trpv4 inhibitors and methods of using the same for organ-specific inflammation and itch
US11229628B2 (en) 2015-01-09 2022-01-25 Duke University TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch
CA3020364A1 (en) 2016-04-07 2017-10-12 Duke University Small molecule dual-inhibitors of trpv4 and trpa1 for sanitizing and anesthetizing
JP6994061B2 (ja) 2019-02-15 2022-01-14 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
CA3130038A1 (en) 2019-02-15 2020-08-20 Novartis Ag Methods for treating ocular surface pain
CN114605408B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 5-羟基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002076946A2 (en) * 2001-03-26 2002-10-03 Novartis Ag Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain.
GB0229808D0 (en) * 2002-12-20 2003-01-29 Glaxo Group Ltd Novel compositions
KR100867188B1 (ko) 2003-12-30 2008-11-06 유로-셀띠끄 소시에떼 아노님 통증 치료에 유용한 피페라진
GB0412769D0 (en) * 2004-06-08 2004-07-07 Novartis Ag Organic compounds
WO2006007851A2 (en) * 2004-07-19 2006-01-26 Novo Nordisk A/S Capsaicin inhibitors for treating obesity and-related disorders
MX2007013931A (es) * 2005-05-12 2008-01-11 Amgen Inc Agentes antipireticos contra incrementos en la temperatura corporal inducidos por antagonista del receptor vainilloide 1.
AU2006330278A1 (en) * 2005-12-28 2007-07-05 Japan Tobacco Inc. 3,4-dihydrobenzoxazine compound and inhibitor of vanilloid receptor type 1 (VR1) activity

Also Published As

Publication number Publication date
AR067631A1 (es) 2009-10-21
CN101754774B (zh) 2013-08-21
ES2648225T3 (es) 2017-12-29
TN2010000004A1 (en) 2011-09-26
WO2009010529A1 (en) 2009-01-22
CN101754774A (zh) 2010-06-23
MY147952A (en) 2013-02-15
CO6270239A2 (es) 2011-04-20
CA2692655A1 (en) 2009-01-22
BRPI0813825A2 (pt) 2015-01-06
TW200914022A (en) 2009-04-01
KR20100039410A (ko) 2010-04-15
JP5755879B2 (ja) 2015-07-29
EP2178562A1 (en) 2010-04-28
MA31563B1 (fr) 2010-08-02
GT201000012A (es) 2012-03-30
EP2178562B1 (en) 2017-08-23
NZ582496A (en) 2012-06-29
EA201000103A1 (ru) 2010-06-30
US8618120B2 (en) 2013-12-31
AU2008277627B2 (en) 2011-10-27
CL2008002096A1 (es) 2009-06-05
US20100144740A1 (en) 2010-06-10
ZA201000076B (en) 2010-09-29
JP2010533679A (ja) 2010-10-28
AU2008277627A1 (en) 2009-01-22

Similar Documents

Publication Publication Date Title
ECSP109883A (es) Combinaciones sinérgicas de antagonistas de vr-1 e inhibidores de cox-2
NL301090I1 (nl) Entrectinib, dan wel tautomeren, of farmaceutisch aanvaardbare zouten daarvan
GT200900283A (es) "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
UY31017A1 (es) Uso de un inhibidor del factor &(alfa) de necrosis tumoral mas un antihistaminico para el tratamiento de la rinitis alérgica y la conjuntivitis alérgica.
NI201100158A (es) Formulaciones de 4 - amino - 2 - (2, 6 - dioxopiperidina - 3 - il) isoindolina - 1, 3 - diona
DK1981889T3 (da) Cytotoksiske midler, der omfatter nye tomaymycin-derivater, og terapeutisk anvendelse deraf
CR10379A (es) Composiones farmaceuticas de antagonistas del anticuerpo anti-cd40.
DK2079688T3 (da) Glucagonreceptorantagonist-forbindelser, sammensætninger indeholdende sådanne forbindelser og deres farmaceutiske anvendelse
CL2008003798A1 (es) Compuestos derivados de heterobiciclos aromaticos sustituidos, inhibidores de pi3 quinasa; composicion farmaceutica; utiles en el tratamiento de cancer, melanomas, glioblastomas, entre otras enfermedades.
DE602008002934D1 (de) 2-cyclopropylthiazolderivate
UY29322A1 (es) Inhibidores de cxcr2
BR112017017135A2 (pt) inibidores de tgf-beta
CL2015002534A1 (es) Formulaciones combinadas de neosaxitoxina para una anestesia local prolongada
NI200900040A (es) Derivados de quinazolinona 5-substituidos como agentes antitumorales.
DK2019104T3 (da) Cytotoksiske midler, der omfatter nye tomaymycinderivater, og terapeutisk anvendelse deraf
EA201190142A1 (ru) Производные пиразола, используемые в качестве антагонистов рецептора ccr4
RS54608B1 (en) CGRP RECEPTOR ANTAGONITY
CL2009000873A1 (es) Compuestos derivados de ciclohepta[b]piridina, antagonistas del receptor de cgrp; composicion farmaceutica; y uso para el tratamiento de la migrana.b
CO6290644A2 (es) Antagonista del receptor opioide selectivo kappa.
PA8809601A1 (es) Combinación anti-retroviral
EA201100358A1 (ru) Дабигатран для чрескожной хирургической катетеризации сердца
UY35354A (es) Combinaciones que comprenden compuestos maba y corticosteroides
NI201300106A (es) Composición farmacéutica antihipertensiva
CO2022005861A2 (es) Terapia de combinación con 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
AR067813A1 (es) Fenilendiaminas sustituidas como inhibidores de l ainteraccion entre mdm2 y p53